|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Date | 14/07/2023 |  |  | Deadline |  |  |

|  |
| --- |
| CONTACT |

|  |  |  |  |
| --- | --- | --- | --- |
| **Organisation** | **Luxembourg Institute of Health** | **Department** | Department of Precision Health |
| **Contact person** | Yvan DevauxGroup Leader, Cardiovascular Research Unit | **Email** | Yvan.Devaux@lih.lu |
| **City** | Luxembourg | **Website** | <https://cvru.lih.lu/>  |
| **Country** | Luxembourg |  |  |

|  |
| --- |
| **Organisation type** |

|  |  |  |  |
| --- | --- | --- | --- |
| **Research organisation type** | [x]  Research Organisation[ ]  University[ ]  Company[ ]  Other  | **Is your company a Small and Medium Sized Enterprise (SME\*)?****Number of employees:** | [ ]  YES [x]  NO  |

Your enterprise is an SME if:

- it is engaged in **economic activity**

- it has **less than 250 employees**

- it has either an **annual turnover not exceeding €50M**, **or an balance sheet total not exceeding €43M**

- it is **autonomous**

*For the definition of SMEs, look at:* [*http://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition\_en*](http://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition_en)

|  |
| --- |
| **Short introduction of key areas of institute’s research:**The Luxembourg Institute of Health is active in translational research in the fields of precision health, oncology and infection/immunity.  |

|  |  |
| --- | --- |
| **Former participation in an FP European project?****Project title / Acronym:****Activities performed:** | [ ]  NO* Chair of EU-CardioRNA COST Action

[www.cardiorna.eu](http://www.cardiorna.eu) * Co-chair of EU-AtheroNET COST Action

<https://www.cost.eu/actions/CA21153/>* Partner of IMI2 CARDIATEAM project ([www.cardiateam.eu](http://www.cardiateam.eu))
* Coordinator of H2020 COVIRNA project ([www.covirna.eu](http://www.covirna.eu) ).
 |

|  |
| --- |
| **Expertise / Commitment offered** |

|  |  |
| --- | --- |
| **Description of your expertise:** | Development of RNA-based biomarkers and therapeutic approaches to personalise health care in multiple disease conditions. Our current focus is on the brain-heart axis with projects related to heart failure, cardiac arrest, diabetes, atherosclerosis, acute coronary syndrome and Parkinson’s disease.  |
|  |  |
| **Keywords specifying your expertise:** | BiomarkersRNANoncoding RNAPersonalized medicineCardiovascular diseaseHeart diseaseCerebrovascular diseaseBrain disease |
|  |  |
| **Commitment offered:** | [x]  Research [ ]  Demonstration [ ]  Training [x]  Technology [ ]  Dissemination [ ]  Other:   |

|  |  |  |  |
| --- | --- | --- | --- |
| **Interested in participation in project types:** | [x]  Research & Innovation Action | [x]  Innovation Action | [x]  EIC Pathfinder |

|  |
| --- |
| Work Programme research areas: indicate your interest |

|  |
| --- |
| Horizon Europe Cluster 1 – Health |

|  |
| --- |
| **Call topic(s):** HORIZON-HLTH-2024-DISEASE- 03-13: Validation of fluid-derived biomarkers for the prediction and prevention of brain disorders. |

|  |  |
| --- | --- |
|  | Validation of newly discovered blood RNA biomarkers of Parkinson Disease |

|  |
| --- |
| Profile of partner sought |

|  |  |  |  |
| --- | --- | --- | --- |
| **Role** | [ ]  technology development | [ ]  research | [ ]  training |
|   | [ ]  dissemination | [ ]  demonstration | [ ]  other \_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| **Country /region** | [ ]   |
| **Expertise required**  |  |

**I agree with the publication of my contact data:** [x]  YES [ ]  NO